Date: 2015-02-27
Type of information: Private placement
Company: Celldex Therapeutics (USA - NJ)
Investors:
Amount: $24.7 million
Funding type: private placement
Planned used: Celldex anticipates using the net proceeds from the offering to fund clinical trials of its product candidates, expansion of its pipeline, expansion of the commercial team and for working capital and other general corporate purposes.
Others: * On February 27, 2015, Celldex Therapeutics announced that the underwriters of its previously announced public offering of common stock have exercised in full their option to purchase an additional 1,087,500 shares of common stock at the public offering price of $24.00. Proceeds to Celldex from the exercise of the underwriters' option will be approximately $24.7 million, after deducting underwriting discounts and commissions. The offering is expected to close on or about March 3, 2015, subject to customary closing conditions. * On February 25, 2015, Celldex Therapeutics announced the pricing of an underwritten public offering of 7,250,000 shares of its common stock, offered at a price to the public of $24.00 per share for an aggregate offering of $174.0 million of common stock. The net proceeds to Celldex from this offering are expected to be approximately $164.2 million after deducting underwriting discounts and commissions and other estimated offering expenses payable by Celldex. The underwriters have been granted a 30-day option to purchase up to an aggregate of 1,087,500 additional shares of common stock. The offering is expected to close on or about March 3, 2015 , subject to customary closing conditions. * On February 24, 2015, Celldex Therapeutics announced that it is offering 7.25 million shares of its common stock in a proposed underwritten public offering. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The shares will be issued pursuant to a prospectus supplement to be filed as part of a shelf registration statement filed with the Securities and Exchange Commission (SEC) on Form S-3. Jefferies LLC and Leerink Partners LLC are acting as the joint book-running managers and underwriters for the proposed offering and Guggenheim Securities, LLC is acting as a lead manager in the offering.
Therapeutic area: Cancer - Oncology
